AR082390A1 - Terapia de combinacion para tratar el cancer que comprende un inhibidor del igf-1r y un inhibidor de akt - Google Patents
Terapia de combinacion para tratar el cancer que comprende un inhibidor del igf-1r y un inhibidor de aktInfo
- Publication number
- AR082390A1 AR082390A1 ARP110102708A ARP110102708A AR082390A1 AR 082390 A1 AR082390 A1 AR 082390A1 AR P110102708 A ARP110102708 A AR P110102708A AR P110102708 A ARP110102708 A AR P110102708A AR 082390 A1 AR082390 A1 AR 082390A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody
- inhibitor
- administration
- antigen binding
- disorder
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Un procedimiento para tratar el cáncer mediante administración de un anticuerpo específico del IGF-1R en combinación con un agente antitumoral un ejemplo del cual es un inhibidor de la vía de Akt. Las cantidades del primero y el segundo juntos comprenden una cantidad terapéuticamente eficaz.Reivindicación 1: Un procedimiento para tratar un trastorno hiperproliferativo en un paciente que sufre el trastorno, que comprende administrar al paciente una combinación de un anticuerpo aislado o un fragmento de unión a antígeno del mismo que se une específicamente al receptor del factor de crecimiento similar a la insulina humana 1 y un inhibidor de ATk, en el que la administración de la combinación tiene como resultado una potenciación de la eficacia terapéutica en el tratamiento del trastorno con respecto a la administración del anticuerpo o un fragmento de unión a antígeno del mismo solo, en el que el anticuerpo o un fragmento de unión a antígeno del mismo comprende las regiones CDR1, CDR2 y CDR3 de una inmunoglobulina de cadena ligera que comprende una secuencia de aminoácidos expuesta en la SEC ID Nº 7; y las regiones CDR1, CDR2 y CDR3 de una inmunoglobulina de cadena pesada que comprende una secuencia de aminoácidos que se expone en la SEC ID Nº 8. Reivindicación 3: El procedimiento de la reivindicación 1, en el que el anticuerpo o fragmento de unión a antígeno del mismo es un anticuerpo que es dalotuzumab. Reivindicación 4: El procedimiento de acuerdo con la reivindicación 1, en el que dicho inhibidor de Akt es MK-2206.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36837410P | 2010-07-28 | 2010-07-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR082390A1 true AR082390A1 (es) | 2012-12-05 |
Family
ID=45530667
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110102708A AR082390A1 (es) | 2010-07-28 | 2011-07-27 | Terapia de combinacion para tratar el cancer que comprende un inhibidor del igf-1r y un inhibidor de akt |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20130287763A1 (es) |
| EP (1) | EP2598168A4 (es) |
| AR (1) | AR082390A1 (es) |
| TW (1) | TW201208702A (es) |
| WO (1) | WO2012015741A2 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009085216A2 (en) | 2007-12-20 | 2009-07-09 | Squicor | Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease |
| US20140079665A1 (en) * | 2011-05-18 | 2014-03-20 | Merck Sharp & Dohme Corp. | Therapeutic anti-igf1r combinations |
| US20140189897A1 (en) | 2011-06-21 | 2014-07-03 | Mayo Foundation For Medical Education And Research | Transgenic animals capable of being induced to delete senescent cells |
| US20140341922A1 (en) * | 2011-11-25 | 2014-11-20 | SUN R & D Foundation | Method for Overcoming Tolerance to Targeted Anti-Cancer Agent |
| WO2013090645A1 (en) | 2011-12-13 | 2013-06-20 | Buck Institute For Research On Aging | Methods for improving medical therapies |
| WO2013158664A2 (en) | 2012-04-17 | 2013-10-24 | Kythera Biopharmaceuticals, Inc. | Use of engineered viruses to specifically kill senescent cells |
| WO2013169611A1 (en) * | 2012-05-09 | 2013-11-14 | Merck Sharp & Dohme Corp. | Compositions and methods for treating breast cancer |
| US9901081B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse for determining the role of senescent cells in cancer |
| US9901080B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells |
| US10279018B2 (en) | 2012-12-03 | 2019-05-07 | Unity Biotechnology, Inc. | Immunogenic compositions for inducing an immune response for elimination of senescent cells |
| WO2015097667A2 (en) * | 2013-12-23 | 2015-07-02 | Cellworks Group, Inc., | A composition, process of preparation of said composition, kit and a method of treating cancer |
| US20170216286A1 (en) | 2014-01-28 | 2017-08-03 | Mayo Foundation For Medical Education And Research | Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid |
| MX2016009753A (es) | 2014-01-28 | 2017-07-07 | Buck Inst For Res On Aging | Metodos y composiciones para exterminar celulas senescentes y para tratar enfermedades y trastornos asociados con la senectud. |
| US10328058B2 (en) | 2014-01-28 | 2019-06-25 | Mayo Foundation For Medical Education And Research | Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques |
| EP3493818A4 (en) * | 2016-08-07 | 2020-04-29 | The Wistar Institute Of Anatomy And Biology | METHODS FOR DETECTION AND TREATMENT OF A PT346 PDK1 EXPRESSING TUMOR |
| GB202201819D0 (en) * | 2022-02-11 | 2022-03-30 | Genome Res Ltd | Methods of treatment |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020081294A1 (en) * | 1996-01-23 | 2002-06-27 | Genentech, Inc. | Co-administration of a thrombolytic and an anti-CD18 antibody in stroke |
| US7241444B2 (en) * | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
| DE602005015542D1 (de) * | 2004-01-12 | 2009-09-03 | Applied Molecular Evolution | Varianten der fc-region |
| EP1979002A2 (en) * | 2005-12-19 | 2008-10-15 | OSI Pharmaceuticals, Inc. | Combination of igfr inhibitor and anti-cancer agent |
| KR20100052545A (ko) * | 2007-08-28 | 2010-05-19 | 바이오겐 아이덱 엠에이 인코포레이티드 | Ｉｇｆ―１ｒ의 다중 에피토프에 결합하는 조성물 |
| US9110082B2 (en) * | 2009-11-30 | 2015-08-18 | Merck Sharp & Dohme Corp. | Methods for the identification and treatment of patients sensitive to anti IGF-1R inhibition therapy |
-
2011
- 2011-07-25 WO PCT/US2011/045191 patent/WO2012015741A2/en active Application Filing
- 2011-07-25 EP EP11813007.9A patent/EP2598168A4/en not_active Withdrawn
- 2011-07-25 US US13/812,249 patent/US20130287763A1/en not_active Abandoned
- 2011-07-27 AR ARP110102708A patent/AR082390A1/es not_active Application Discontinuation
- 2011-07-27 TW TW100126660A patent/TW201208702A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201208702A (en) | 2012-03-01 |
| WO2012015741A2 (en) | 2012-02-02 |
| WO2012015741A3 (en) | 2012-03-29 |
| US20130287763A1 (en) | 2013-10-31 |
| EP2598168A4 (en) | 2014-03-26 |
| EP2598168A2 (en) | 2013-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR082390A1 (es) | Terapia de combinacion para tratar el cancer que comprende un inhibidor del igf-1r y un inhibidor de akt | |
| PH12021550023A1 (en) | Humanized anti-tau antibodies | |
| CL2020002945A1 (es) | Métodos para tratar cánceres y potenciar la eficacia de agentes terapéuticos para el redireccionamiento de células t | |
| CY1121148T1 (el) | Παραγοντες συνδεσης vegf/dll4 και χρησεις αυτων | |
| MX2018014950A (es) | Terapia de combinacion. | |
| HRP20231156T1 (hr) | Kombinacija anti-pd-1 antitijela i bispecifičnih anti-cd20/anti-cd3 antitijela za liječenje raka | |
| EA201490957A1 (ru) | Лечение гематологических злокачественных заболеваний с помощью анти-cxcr4 антитела | |
| AR126019A1 (es) | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación | |
| AR079903A1 (es) | Formulacion de anticuerpo y regimenes terapeuticos. envase farmaceutico. kit. | |
| AR104213A1 (es) | Anticuerpos anti-cd38 como agentes terapéuticos | |
| RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
| AR080698A1 (es) | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e | |
| UA94899C2 (ru) | Фиксированное дозирование антител к her | |
| RU2018123717A (ru) | Комбинированные лечения, их применения и способы | |
| UA102775C2 (uk) | Спосіб лікування болю із застосуванням анти-ngf антитіла | |
| EA201590144A1 (ru) | Rspo3-связывающие агенты и их применение | |
| MY173234A (en) | Method of treating cancer with dll4 antagonist and chemotherapeutic agent | |
| AR109533A2 (es) | Anticuerpos anti-fractalkina o un fragmento de unión a la fkn de éste, composiciones que lo comprenden y métodos para tratar trastornos inflamatorios | |
| AR070821A1 (es) | Anticuerpo anti- tyrp1 (antitiroxina humana) | |
| GEP20135826B (en) | Novel antibodies used to treat cancer | |
| EA201890805A1 (ru) | Биспецифические антитела против cd3*cd19 | |
| WO2011101328A3 (en) | Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor | |
| JP2015096065A5 (es) | ||
| NZ595755A (en) | Combination therapy using an anti-egfr agent(s) and igf-1r specific inhibitors | |
| ZA201907754B (en) | Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |